| abstract |
The present invention provides a method for reducing the heart size and/or delaying the onset of clinical symptoms in a patient suffering from asymptomatic (latent, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD); and/or as pimobendan for use in a method of delaying the onset of heart failure, preferably congestive heart failure, in a patient suffering from asymptomatic (latent, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD). , wherein said patient is preferably a mammal, more preferably a human, dog, cat or horse, most preferably an individual. |